Common Contracts
8 similar Underwriting Agreement contracts by BioSig Technologies, Inc., Amesite Inc., Rain Therapeutics Inc., others
6,861,080 Shares of Common Stock 1,715,250 Shares of Non-Voting Common Stock RAIN THERAPEUTICS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 7th, 2022 • Rain Therapeutics Inc. • Pharmaceutical preparations • New York
Rain Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 8,576,330 shares (the “Firm Shares”), which comprise (i) 6,861,080 shares of its voting common stock, par value $0.001 per share (the “Voting Common Stock”) and (ii) 1,715,250 shares of its non-voting common stock, par value $0.001 per share (the “Non-Voting Common Stock” and, together with the Voting Stock, the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 1,286,449 shares (the “Additional Shares”) of Voting Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim S
4,341,667 Shares BIOSIG TECHNOLOGIES, INC. Common Stock AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2022 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”), on a best efforts basis, 4,341,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). This Amended and Restated Underwriting Agreement amends, restates and supersedes in its entirety the prior underwriting agreement dated as of June 24, 2022, by and between the Company and the Representative.
4,666,667 Shares BIOSIG TECHNOLOGIES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 29th, 2022 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”), on a best efforts basis, 4,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
AMESITE INC. Common Stock AMENDED AND RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2022 • Amesite Inc. • Services-prepackaged software • New York
Amesite Inc. (f/k/a Amesite Operating Company), a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement, on a best efforts basis, up to 3,750,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). This Amended and Restated Underwriting Agreement (this “Agreement”) amends, restates and supersedes in its entirety the prior Underwriting Agreement dated February 11, 2022 (the “Original Signing Date”) by and between the Company and the Underwriters.
2,500,000 Shares BIOSIG TECHNOLOGIES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 6th, 2021 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”) 2,500,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to 375,000 additional shares of Common Stock on the terms set forth in Section 2 (the “Option Shares”). The Firm Shares and the Option Shares, if and to the extent such option is exercised, are hereinafter collectively called the “Shares.”
RBB BANCORP Underwriting AgreementUnderwriting Agreement • March 26th, 2021 • RBB Bancorp • State commercial banks • New York
RBB Bancorp, a California corporation (the “Company”) confirms its agreement with the several Underwriters listed on Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), with respect to the issue and sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of the respective principal amounts set forth in Schedule I of $120,000,000 in aggregate principal amount of the Company’s 4.00% Fixed-to-Floating Rate Subordinated Notes due 2031 (the “Securities”). The Securities are to be issued pursuant to the Subordinated Indenture dated as of March 26, 2021 (the “Base Indenture”), by and between the Company and Wilmington Trust, National Association, as trustee (the “Trustee”), as supplemented by a supplemental indenture, to be dated as of March 26, 2021 (the “Supplemental Indenture”), by and between the Company and the Trustee (the Base Indenture, as supplemented by the Supplemental Indenture, the “Indentu
BIOSIG TECHNOLOGIES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 24th, 2020 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”), on a best efforts basis, 2,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
SIRONA DENTAL SYSTEMS, INC. 10,147,480 Shares of Common Stock, $0.01 par value Underwriting AgreementUnderwriting Agreement • May 11th, 2011 • Sirona Dental Systems, Inc. • Dental equipment & supplies • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of Sirona Dental Systems, Inc., a Delaware corporation (the “Company”), propose to sell to you (the “Underwriter”), an aggregate of 10,147,480 shares of common stock, par value $0.01 per share, of the Company (the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
